Background <p>We have demonstrated that mild suppression of thyrotropin (TSH) using levothyroxine (LT<sub>4</sub>) is necessary to achieve normal free triiodothyronine (FT<sub>3</sub>) levels and a metabolic euthyroid state in athyreotic patients. Consequently, management strategies based on thyroid volume (TV) have been implemented in patients receiving LT<sub>4</sub> at Kuma Hospital. While Hashimoto’s thyroiditis (HT) can vary from atrophic to diffusely enlarged thyroid volumes.</p> Methods <p>In this retrospective study, we aimed to evaluate the composition of thyroid hormone measurement items (serum FT<sub>4</sub>, FT<sub>3</sub>, and FT<sub>4</sub>+FT<sub>3</sub>) in patients receiving LT<sub>4</sub> monotherapy for HT, stratifying them by TV, as assessed using ultrasonography.</p> Results <p>We identified 7,576 consecutive patients from their medical records. These patients were classified into five groups based on TV: atrophic thyroid (TV ≤ 10 mL); normal thyroid (TV 10–20 mL); mildly enlarged thyroid (TV 20–50 mL); moderately enlarged thyroid (TV 50–80 mL); and large thyroid (TV &gt; 80 mL). In all patient groups, FT<sub>4</sub> measurements constituted the majority or nearly half of all assessments. However, the proportion of FT<sub>3</sub> measurements increased notably in the atrophic thyroid group (34%) and in the large goiter group (29%). Patients receiving LT<sub>4</sub> were evaluated based on their TSH levels. In the reduced TSH group, FT<sub>3</sub> accounted for nearly half of all measurements (47%). Conversely, in the normal TSH group, FT<sub>4</sub> accounted for the majority of all measurements (76%).</p> Conclusion <p>This study revealed that FT<sub>3</sub>, rather than FT<sub>4</sub>, was the predominant thyroid hormone measured in a significant number of patients with HT on LT<sub>4</sub> monotherapy at our hospital. Furthermore, our study highlights a management approach whereby TSH levels were intentionally suppressed in some patients.</p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

Thyroid hormone measurement items in patients with Hashimoto’s thyroiditis on levothyroxine monotherapy: management based on thyroid tissue volume

  • Mitsuru Ito,
  • Yoshiki Furumura,
  • Itaru Monno,
  • Hanna Deguchi-Horiuchi,
  • Chisako Imamura,
  • Sawako Takahashi,
  • Hiroyuki Yamaoka,
  • Mako Hisakado,
  • Kazuyoshi Kohsaka,
  • Eijun Nishihara,
  • Shuji Fukata,
  • Mitsushige Nishikawa,
  • Akira Miyauchi,
  • Takashi Akamizu

摘要

Background

We have demonstrated that mild suppression of thyrotropin (TSH) using levothyroxine (LT4) is necessary to achieve normal free triiodothyronine (FT3) levels and a metabolic euthyroid state in athyreotic patients. Consequently, management strategies based on thyroid volume (TV) have been implemented in patients receiving LT4 at Kuma Hospital. While Hashimoto’s thyroiditis (HT) can vary from atrophic to diffusely enlarged thyroid volumes.

Methods

In this retrospective study, we aimed to evaluate the composition of thyroid hormone measurement items (serum FT4, FT3, and FT4+FT3) in patients receiving LT4 monotherapy for HT, stratifying them by TV, as assessed using ultrasonography.

Results

We identified 7,576 consecutive patients from their medical records. These patients were classified into five groups based on TV: atrophic thyroid (TV ≤ 10 mL); normal thyroid (TV 10–20 mL); mildly enlarged thyroid (TV 20–50 mL); moderately enlarged thyroid (TV 50–80 mL); and large thyroid (TV > 80 mL). In all patient groups, FT4 measurements constituted the majority or nearly half of all assessments. However, the proportion of FT3 measurements increased notably in the atrophic thyroid group (34%) and in the large goiter group (29%). Patients receiving LT4 were evaluated based on their TSH levels. In the reduced TSH group, FT3 accounted for nearly half of all measurements (47%). Conversely, in the normal TSH group, FT4 accounted for the majority of all measurements (76%).

Conclusion

This study revealed that FT3, rather than FT4, was the predominant thyroid hormone measured in a significant number of patients with HT on LT4 monotherapy at our hospital. Furthermore, our study highlights a management approach whereby TSH levels were intentionally suppressed in some patients.